The coronavirus pandemic is currently presenting various challenges to clinical healthcare providers and patients across the globe. Logistical issues, managing patients with the disease, prioritizing patients with comorbidities and pre-existing conditions, and protecting public & hospital frontline workers from exposure to the COVID-19 infection are the major challenges faced by healthcare systems across the globe.



The coronavirus pandemic is currently presenting various challenges to clinical healthcare providers and patients across the globe. Logistical issues, managing patients with the disease, prioritizing patients with comorbidities and pre-existing conditions, and protecting public & hospital frontline workers from exposure to the COVID-19 infection are the major challenges faced by healthcare systems across the globe.



During the COVID-19 pandemic, a 90% drop was observed in the number of people undergoing IVF cycles. The spread of COVID-19 has not only impacted fertility clinics owing to the cancellation of IVF treatments but has also impacted fertility decisions among couples who were opting for IVF treatment before the pandemic.



Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43497112



[255 Pages Report] The global infertility treatment size is projected to reach USD 2.2 billion by 2026 from USD 1.5 billion in 2021, at a CAGR of 8.1 % during the forecast period. Growth in the infertility treatment market is primarily driven by factors such as the declining fertility rate, rising number of fertility clinics worldwide, technological advancements, and increasing public-private investments, funds, and grants.



Along with fertility surgeries, thousands of cycles of ART procedures such as in vitro fertilization (IVF) are performed every year globally. The cost of IVF treatment varies from country to country due to the lack of reimbursement policies.



Additionally, the medical tourism industry in emerging countries is thriving owing to a number of factors. In Asia, healthcare facilities are of high quality, treatment procedures are affordable, and many of the doctors and surgeons are trained and educated in the top institutes in the US and Europe.



Assisted reproductive technology (ART) involves procedures that require the handling of the human egg and embryos. Since the inception of ART procedures, there have been various ethical, legal, and societal controversies regarding the safe administration of gonadotropins, transparency of pregnancy data from clinics, and addressing economic barriers to ART access.



The prominent players operating in the global infertility treatment market include The Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher Scientific, Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Biomedx (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker Company, Inc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), IHMedical A/S (Denmark), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), MedGyn Products, Inc. (US).